The anti-CD16 component is combined with one or two tumor antigen-specific antibodies such as CD19/20 in B cell malignancies [104–107], CD33/CD123 in AML [108–110], CD30 in Hodgkin’s lymphoma [111], and HLA class II in lymphoma [112]. The gene discussed is FCGR3A; the disease is neoplasm.